MAYO CLINIC LABORATORIES

NEW TEST

Notification Date: March 25, 2025
Effective Date: April 17, 2025

Neuro-Oncology Gene Panel, Mutations Only, Tumor

Test ID: NONCM

Useful for:

- Identifying mutations that may support a diagnosis or help determine prognosis for patients with central nervous system tumors
- Identifying specific mutations within genes known to be associated with response or resistance to specific cancer therapies
- This test is **not intended** for use for hematological malignancies.

Ordering Guidance:

Multiple oncology (cancer) gene panels are available. For more information see Hematology, Oncology, and Hereditary Test Selection Guide.

Testing Algorithm

When this test is ordered, slide review will always be performed at an additional charge.

Reflex Tests:

Test ID	Reporting Name	Available Separately	Always Performed
SLIRV	Slide Review in MG	No (Bill Only)	Yes

Methods:

Sequence Capture Next-Generation Sequencing (NGS)

Reference Values:

An interpretive report will be provided.

Specimen Requirements:

This assay requires at least 20% tumor nuclei.
-Preferred amount of tumor area with sufficient percent tumor nuclei: tissue 288 mm(2)
-Minimum amount of tumor area: tissue 36 mm(2)

-If ordered in conjunction with CMAPT / Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded, the preferred amount of tissue is 430 mm(2), the minimum amount is 180 mm(2).
-These amounts are cumulative over up to 15 unstained slides and must have adequate percent tumor nuclei.
-Tissue fixation: 10% neutral buffered formalin, not decalcified
- For this test, at least 6 mm x 6 mm areas on 8 unstained slides is preferred: this is approximately equivalent to 288 mm(2). The minimum acceptable area is 6 mm x 6 mm on 1 unstained slides: approximately equivalent to 36 mm(2). For specimen preparation guidance, see Tissue Requirement for Solid Tumor Next-Generation Sequencing.

Preferred:	
Specimen Type:	Tissue block
Collection Instructions:	Submit a formalin-fixed, paraffin-embedded tissue block with acceptable amount of tumor tissue.
Acceptable:	
Specimen Type:	Tissue slide
Slides:	1 Hematoxylin and eosin-stained and 15 unstained
Collection Instructions:	Submit the followings slides: 1 Slide stained with hematoxylin and eosin AND 15 Unstained, nonbaked slides with 5-micron thick sections of the tumor tissue.
Note:	The total amount of required tumor nuclei can be obtained by scraping up to 15 slides from the same block.
Additional Information:	Unused unstained slides will not be returned.

Necessary Information:

Pathology report (final or preliminary), at minimum containing the following information, must accompany specimen for testing to be performed:

1. Patient name
2. Block number-must be on all blocks, slides, and paperwork (can be handwritten on the paperwork)
3. Tissue collection date
4. Source of the tissue

Specimen Stability Information:

Specimen Type	Temperature	Time	Special Container
Varies	Ambient (preferred)		
	Refrigerated		

Cautions:

- This test does not include evaluation of rearrangements (fusions and abnormal transcript variants).
- This test cannot differentiate between somatic and germline alterations. Additional testing may be necessary to clarify the significance of results if there is a potential hereditary risk.
- Variants of uncertain significance may be identified.

- A negative result does not rule out the presence of a variant that may be present below the limits of detection of this assay. The analytical sensitivity of this assay for sequence reportable alterations is 5% mutant allele frequency with a minimum coverage of 500X in a sample with 20% or more tumor content.
- Point mutations and small insertion/deletion mutations will be detected in 89 genes. This test may detect single exon deletions but does not detect multi-exon deletions, duplications, or genomic copy number variants in any of the genes tested
- The presence or absence of a variant may not be predictive of response to therapy in all patients.
- Rare alterations (ie, polymorphisms) may be present that could lead to false-negative or false-positive results.
- Test results should be interpreted in the context of clinical, tumor sampling, histopathological, and other laboratory data. If results obtained do not match other clinical or laboratory findings, contact the laboratory for discussion. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.
- Reliable results are dependent on adequate specimen collection and processing. This test has been validated on formalin-fixed, paraffin-embedded tissues; other fixatives are discouraged. Improper treatment of tissues, such as decalcification, may cause polymerase chain reaction failure.
- Genes may be added or removed based on updated clinical relevance. Refer to the Targeted DNA Gene Regions Interrogated by Neuro-Oncology Panel for the most up to date list of genes included in this test.

CPT Code:
81455

Day(s) Performed: Monday through Friday **Report Available:** 12 to 20 days

Questions

Contact Michelle Raths, Laboratory Resource Coordinator at 800-533-1710.